YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation
Cancer Letters · 2024-08 · 597 · 217047
DOI: 10.1016/j.canlet.2024.217047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Shuoer Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Nuclear Medicine, Cancer Institute, F…. Hauptthemen laut MEDLINE: Bone Neoplasms, Breast Neoplasms, Cadherins, Enhancer of Zeste Homolog 2 Protein. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Bone metastasis is common in breast cancer and more effective therapies are required, however, its molecular mechanism is poorly understood. Additionally, the role of the m6A reader YTHDF1 in bone metastasis of breast cancer has not been reported. Here, we reveal that the increased expression of YTHDF1 is clinically correlated with breast cancer bone metastases. YTHDF1 promotes migration, invasion, and osteoblast adhesion and induces osteoclast differentiation of cancer cells in vitro and vivo. Mechanically, RNA-seq, MeRIP-seq and RIP-seq analysis, and molecular biology experiments demonstrate that YTHDF1 translationally enhances EZH2 and CDH11 expression by reading m6A-enriched sites of their transcripts. Moreover, adeno-associated virus (AAV) was used to deliver shYTHDF1 (shYTHDF1-AAV) in intratibial injection models, eliciting a significant suppressive effect on breast cancer bone metastatic formation and osteolytic destruction. Overall, we uncovered that YTHDF1 promotes osteolytic bone metastases of breast cancer by inducing EZH2 and CDH11 translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Nuclear Medicine, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; Department of…
- Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Nuclear Medicine, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, China; In…
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Xu, L., Wang, D., Zhao, S., Li, K., Ma, F., Yao, Q., Zhang, Y., Wu, Z., Shao, Y., Song, S., & Yan, W. (2024). YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation. Cancer Letters, 597, 217047. https://doi.org/10.1016/j.canlet.2024.217047
Vancouver
Wang S, Xu L, Wang D, Zhao S, Li K, Ma F, et al. YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation. Cancer Letters. 2024;597:217047. doi:10.1016/j.canlet.2024.217047
BibTeX
@article{Wang2024,
author = {Wang, Shuoer and Xu, Lun and Wang, Dongliang and Zhao, Songjiao and Li, Kun and Ma, Fen and Yao, Qianlan and Zhang, Yunkui and Wu, Zhiqiang and Shao, Yang and Song, Shaoli and Yan, Wangjun},
title = {YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation},
journal = {Cancer Letters},
year = {2024},
volume = {597},
pages = {217047},
doi = {10.1016/j.canlet.2024.217047}
}
EUVIMED